Nexalin Technology, Inc. NXL

Nexalin Technology reports secondary analysis of prior clinical trial data showing unreported gains in memory, comprehension and language function for Alzheimer’s patients. ADAS-Cog subscale results will guide design of planned U.S. pilot study. Positive Alzheimer’s data analysis advances development pipeline and supports new pilot study with potential to lift valuation and market position.

Nexalin Technology announces two clinical abstracts accepted for presentation at the 2026 NYC Neuromodulation Conference highlighting preliminary clinical results across anxiety, depression, insomnia and quality of life. Conference acceptance of preliminary clinical data can moderately increase visibility and investor interest in Nexalin's neuromodulation technology.

Nexalin Technology's Brazil trial showed 77.8% anxiety response rate plus durable benefits for depression, insomnia and quality of life, supporting product launch and Brazilian sales plan advancement. Positive efficacy data directly enables new market entry and revenue growth for Nexalin's core device.

Nexalin Technology reports Brazil trial results showing benefits across anxiety, sleep and quality of life. Positive Brazil trial data can drive regulatory progress and lift Nexalin valuation.

Nexalin Technology, Inc. receives U.S. patent covering Dynamic Frequency Stimulation technology for treating anxiety, depression and insomnia. Patent grant secures core IP for therapeutic device technology and can materially lift valuation and competitive position.

Nexalin Technology secured a key neurostimulation legislative provision and commended U.S. House report language expanding non-invasive deep brain neurostimulation research at the Department of Veterans Affairs for traumatic brain injury. Legislative win and VA research expansion directly support Nexalin's core non-invasive technology with potential for new funding and adoption in TBI care.

Nexalin acquires AI-integrated digital health platform behind HALO Clarity and Nexalin NeuroCare ahead of planned FDA pivotal trial. Acquisition bolsters AI capabilities for core neurocare products immediately before key FDA trial.

Nexalin Technology, Inc. announces peer-reviewed publication in Psychotherapy and Psychosomatics featuring neuroimaging data demonstrating brain-network effects and clinical improvements in chronic insomnia using its technology. Peer-reviewed neuroimaging data validating brain effects and clinical benefits for chronic insomnia bolsters Nexalin's technology credibility and investor appeal.

Nexalin Technology advances its pivotal clinical trial for HALO™ Clarity neurostimulation device toward Q2 2026 enrollment, marking key progress in treating neurobehavioral disorders. Advancing a pivotal clinical trial for HALO™ Clarity represents a major milestone toward FDA approval and commercialization, potentially transforming NXL's market position.

Nexalin Technology advances FDA Alzheimer’s strategy after landmark leadership meetings with regulators and partners in the U.S. and China. Landmark meetings propel Nexalin's FDA Alzheimer’s strategy forward, enabling major regulatory progress and elevating market potential.

Nexalin Technology, Inc. (NXL) announced a peer-reviewed study demonstrating its DIFS™ technology reduced self-injury and depression symptoms in female adolescents. Peer-reviewed evidence of DIFS™ efficacy in adolescent mental health validates the technology and could boost clinical adoption, partnerships, and stock performance.

Nexalin Technology, Inc. (NXL) announced the pivotal HALO™ Clarity Trial to generate data supporting a planned De Novo FDA submission targeting the multi-billion-dollar insomnia market. Pivotal trial for De Novo FDA submission targets multi-billion-dollar insomnia market, enabling major entry into high-growth sector with potential to alter NXL's trajectory.

Nexalin Technology, Inc. (NXL) participates in and commends recent congressional momentum supporting deep brain neurostimulation research for veterans and neurological disorders. Congressional momentum for deep brain neurostimulation research aligns with Nexalin's core non-invasive neurostimulation technology, likely boosting market sentiment and research opportunities without transformative guarantees.

Nexalin Technology, Inc. (NXL) and First Phosphate are set to be featured on the RedChip Small Stocks, Big Money(TM) Show airing on Bloomberg TV. This appearance aims to highlight the companies' developments and potential in their respective sectors, providing visibility to investors and the market. Increased visibility through media exposure may positively influence investor sentiment and market performance.

Nexalin Technology, Inc. has launched NeuroCare®, an AI-driven virtual clinic aimed at improving access to care for patients suffering from Alzheimer's, mood disorders, traumatic brain injury (TBI), and post-traumatic stress disorder (PTSD). This innovative platform is designed to enhance patient engagement and streamline treatment processes, potentially transforming the landscape of mental health care. The launch of NeuroCare® represents a significant strategic move that could enhance Nexalin's market position and investor sentiment.

Nexalin Technology, Inc. (NXL) has highlighted its growing body of peer-reviewed neuroimaging research that supports its DIFS™ technology as a leader in evidence-based non-invasive brain stimulation. This research underscores the efficacy and potential of Nexalin's technology in treating various neurological conditions, positioning the company favorably within the mental health treatment landscape. The expanding research base for DIFS™ technology is likely to significantly enhance Nexalin's market position and investor sentiment.

A peer-reviewed study has shown that Nexalin Technology, Inc.'s DIFS™ neurostimulation treatment significantly improves attention and normalizes brain activity in patients diagnosed with ADHD. The findings suggest potential therapeutic benefits of this technology for managing ADHD symptoms, indicating a promising avenue for future clinical applications. The study's positive results could significantly enhance Nexalin's market position and investor sentiment regarding its ADHD treatment solutions.

Nexalin Technology, Inc. has successfully completed its FDA Q-Submission meeting for the Gen-2 SYNC™ Neurostimulation Console, which is part of its Alzheimer's Disease program. This meeting is a crucial step in the regulatory process, allowing the company to discuss its development plans and gather feedback from the FDA regarding its neurostimulation technology aimed at treating Alzheimer's. Completion of the FDA Q-Submission meeting is a significant regulatory milestone that could enhance Nexalin's market position and investor sentiment.

Nexalin Technology, Inc. (NXL) is hosting an exclusive live investor webinar and Q&A session on December 4. This event aims to provide insights into the company's developments and future plans, allowing investors to engage directly with the management team. The webinar may influence investor sentiment and provide insights into the company's future, but its overall impact is expected to be limited.

Nexalin Technology, Inc. has reported promising results from its 15 milliamp neurostimulation device in treating gambling disorder, particularly in patients with comorbid alcohol use. The device aims to address the underlying neurological issues associated with these disorders, potentially offering a new therapeutic option for affected individuals. The development of a neurostimulation device targeting gambling disorder with alcohol use comorbidity could significantly enhance Nexalin's market position and investor interest.

Nexalin Technology, Inc. has appointed Carmi Masha Technologies Ltd. as its exclusive distributor in Israel. This partnership aims to enhance the distribution of Nexalin's innovative technology in the region, potentially expanding its market presence and accessibility. The exclusive distribution agreement is a significant strategic move that could enhance market penetration and investor sentiment.

Nexalin Technology, Inc. announced that the U.S. FDA has accepted its Q-Submission for the Gen-2 SYNC device, aimed at treating Alzheimer’s disease and dementia. This acceptance marks a significant step in the regulatory process for the company's innovative treatment approach, potentially paving the way for future clinical advancements. FDA acceptance of the Q-Submission is a critical regulatory milestone that could significantly impact Nexalin's market position and investor sentiment.

Nexalin Technology, Inc. has received regulatory approval to market its Gen 2 SYNC, 15 mA Neurostimulation DIFS™ device in Israel. This device is designed for neurostimulation therapy, potentially expanding the company's market reach and product offerings in the region. Regulatory approval for a new medical device can significantly enhance market presence and revenue potential.

Nexalin Technology, Inc. announced that its DIFS™ Neurostimulation technology has demonstrated cognitive and brain network improvements in patients with Alzheimer’s and dementia, as evidenced by three peer-reviewed studies. These findings suggest potential advancements in treatment options for these conditions, highlighting the efficacy of Nexalin's approach in enhancing cognitive function. The positive results from peer-reviewed studies indicate significant potential for Nexalin's technology to impact its market position and investor sentiment.

Nexalin Technology, Inc. (NXL) and BioVie will be featured in interviews on the RedChip Small Stocks, Big Money(TM) Show, which airs on Bloomberg TV. This exposure aims to highlight their business developments and growth potential to a broader audience, potentially attracting investor interest. Increased media exposure may enhance investor sentiment and interest in Nexalin Technology's growth prospects.

Nexalin Technology, Inc. has expanded its Scientific Advisory Board by appointing Dr. Robert Rothstein, a prominent figure in neuroscience, to enhance its Alzheimer’s and Traumatic Brain Injury programs. This strategic move aims to bolster the company's research and development efforts in addressing these critical health issues. The appointment of a notable expert like Dr. Rothstein is likely to significantly enhance Nexalin's research capabilities and market positioning in the Alzheimer's and TBI sectors.

Nexalin Technology, Inc. (NXL) is exploring growth opportunities through its innovative treatment solutions for mental health disorders. The company aims to expand its market presence and enhance its product offerings, focusing on the increasing demand for non-invasive therapies. With a strategic approach to partnerships and potential regulatory advancements, Nexalin is positioning itself to capitalize on the evolving healthcare landscape. Investors are keenly observing the company's progress as it seeks to deliver on its ambitious growth plans. Nexalin's strategic initiatives and potential market expansion could significantly impact its future performance and investor sentiment.

Nexalin Technology, Inc. (NXL) announced its participation in the 2025 Maxim Growth Summit, a significant event for growth-oriented companies. The summit aims to connect investors with emerging growth companies, providing a platform for NXL to showcase its innovations and engage with potential investors. Attendance at such events is expected to enhance visibility and foster relationships within the investment community. Participation in the summit may enhance investor relations and visibility, but the overall impact on the company's trajectory is expected to be limited.

Nexalin Technology, Inc. announced additional positive clinical results for its Gen-2 SYNC Neurostimulation Device in treating Alzheimer’s Disease. The device aims to improve cognitive function and quality of life for patients. These results build on previous findings, indicating the potential for significant advancements in Alzheimer’s treatment. The company continues to focus on developing innovative solutions for neurological disorders. Positive clinical results for a new treatment in Alzheimer’s Disease could significantly enhance Nexalin's market position and investor sentiment.

Nexalin Technology, Inc. (NXL) has been identified as one of the top midday gainers in the stock market, reflecting a notable increase in its share price. This surge is attributed to positive market sentiment and potential developments surrounding the company's operations. Investors are closely monitoring NXL's performance as it may indicate future growth opportunities and strategic advancements within the company. The increase in share price suggests a moderately noticeable influence on market sentiment and potential growth opportunities.